CN113897360A - Eef1b2 gene knockout zebra fish epilepsy model and application thereof - Google Patents
Eef1b2 gene knockout zebra fish epilepsy model and application thereof Download PDFInfo
- Publication number
- CN113897360A CN113897360A CN202111013471.2A CN202111013471A CN113897360A CN 113897360 A CN113897360 A CN 113897360A CN 202111013471 A CN202111013471 A CN 202111013471A CN 113897360 A CN113897360 A CN 113897360A
- Authority
- CN
- China
- Prior art keywords
- zebra fish
- seq
- eef1b2
- gene
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 73
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 27
- 238000003209 gene knockout Methods 0.000 title description 8
- 101100500670 Mus musculus Eef1b gene Proteins 0.000 title description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 18
- 230000035772 mutation Effects 0.000 claims abstract description 11
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract description 6
- 210000002257 embryonic structure Anatomy 0.000 claims description 20
- 108091033409 CRISPR Proteins 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 101000967447 Homo sapiens Elongation factor 1-beta Proteins 0.000 abstract description 6
- 102100040465 Elongation factor 1-beta Human genes 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 238000010362 genome editing Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000520 microinjection Methods 0.000 description 7
- 238000007480 sanger sequencing Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150024272 Eef1b gene Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 101150075612 EEF1B2 gene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
Abstract
According to the invention, through a CRISPONT technology, a 5bp fragment is inserted into a second exon of a zebra fish eef1b2 gene, and a 3bp fragment is deleted at the same time, so that a eef1b2 gene-deleted zebra fish is bred, and thus a zebra fish epilepsy model is constructed. The invention uses four sgRNAs to target the same gene, so that the editing efficiency can be improved to the maximum extent, and the gene editing can be carried out more effectively. The zebra fish epilepsy model provided by the invention lays a good foundation for further developing the relation research of EEF1B2 mutation and epilepsy pathogenesis and screening antiepileptic drugs.
Description
Technical Field
The invention relates to the technical field of gene knockout, in particular to an eef1b2 gene knockout zebra fish epilepsy model and application thereof.
Background
CRISPR (clustered, regular internationalized, short palindromic repeats) is an immunological mechanism from bacteria to degrade invading viral DNA or other foreign DNA. In bacteria and archaea, CRISPR systems are divided into 3 types, wherein the types I and III need multiple CRISPR-associated proteins (Cas proteins) to play a role together, while the type II system only needs one Cas protein, which provides convenience for wide application. At present, the CRISPR/Cas9 system is most widely used. Researchers found that targeting the same gene with multiple sgrnas could maximize editing efficiency, and named this approach as crisp technology.
In the results of sequencing by complete exome (WES) of the epileptics in the previous period, the gene EEF1B2 which possibly causes epileptic diseases is screened, and no report of EEF1B2 mutant epileptic zebra fish line is found through literature inquiry. Zebrafish, as a vertebrate, have a complex nervous system, are similar in genetic structure to humans, and share approximately 70% of genes with humans, and about 84% of genes related to human diseases are known to be expressed in zebrafish. Compared with rodents such as mice and the like, the zebra fish is simple in genetic operation and more suitable for preparing an epilepsy model. And the zebra fish eef1b2 gene is more conservative in evolution, and the research finds that the eef1b2 has particularly high expression level in the early embryo stage of the zebra fish. Therefore, the invention aims to establish EEF1B2 gene knockout zebra fish epilepsy model by using CRISPONT technology, and the zebra fish can be used for researching the relation between EEF1B2 mutation and epilepsy pathogenesis and screening subsequent antiepileptic drugs.
Disclosure of Invention
The invention provides an EEF1B2 gene knockout zebra fish epilepsy model and application thereof, and lays a foundation for further researching the relation between EEF1B2 mutation and an epilepsy pathogenesis and screening antiepileptic drugs.
The invention adopts the following technical scheme:
the invention provides a zebra fish epilepsy model, which is constructed by knocking out a zebra fish eef1b2 gene by utilizing sgRNA combination, wherein the sgRNA combination sequence is shown as SEQ ID No. 1-SEQ ID No.4, the zebra fish eef1b2 gene is knocked out by inserting a 5bp fragment into a second exon of a zebra fish eef1b2 gene and deleting a 3bp fragment, and the sequences are shown as SEQ ID No.7 and SEQ ID No. 8.
The invention provides an application of sgRNA combination in construction of a zebra fish epilepsy model, which is characterized in that the sgRNA combination is used for knocking out a zebra fish eef1b2 gene to construct the zebra fish epilepsy model, the sgRNA combination sequence is shown in SEQ ID No. 1-SEQ ID No.4, the knocked-out zebra fish eef1b2 gene is obtained by inserting a 5bp fragment into a second exon of a zebra fish eef1b2 gene and deleting a 3bp fragment, and the sequence is shown in SEQ ID No.7 and SEQ ID No. 8.
The third aspect of the invention provides application of the zebra fish epilepsy model in screening antiepileptic drugs.
The fourth aspect of the invention provides a method for constructing a zebra fish epilepsy model, which comprises the following steps:
1) and sgRNA combination of the targeted CRISPONT gene and screening of detection primers: the sgRNA combined sequence is shown in SEQ ID NO.1 to SEQ ID NO.4, and the detection primer sequence is shown in SEQ ID NO.5 to SEQ ID NO. 6;
2) injecting a mixture of 4 sgrnas and Cas9 proteins into fertilized eggs of zebrafish;
3) f0 mutant zebra fish screening: screening out effective embryo, and culturing to adult fish to obtain F0 generation mutant zebra fish;
4) obtaining generations F1 of heritable zebrafish mutants: hybridizing F0 generation mutant zebra fish with wild zebra fish to obtain F1 generation embryos, screening the embryos with mutation, culturing to adult fish, screening to obtain F1 generation of heritable zebra fish mutant, compared with wild type, inserting 5bp fragment into the second exon of eef1b2 gene and deleting 3bp fragment, the sequence is shown as SEQ ID NO.7 and SEQ ID NO. 8.
The invention has the beneficial effects that:
according to the invention, a sgRNA combination of a zebra fish epilepsy model is constructed by specifically knocking out the zebra fish eef1b2 gene through CRISPONT, a 5bp fragment is inserted into a second exon of the zebra fish eef1b2 gene and a 3bp fragment is deleted at the same time through CRISPONT technology, and the zebra fish with eef1b2 gene deletion is bred, so that the zebra fish epilepsy model is constructed.
The invention uses four sgRNAs to target the same gene, so that the editing efficiency can be improved to the maximum extent, and the gene editing can be carried out more effectively.
The zebra fish epilepsy model provided by the invention lays a good foundation for further developing the relation research of EEF1B2 mutation and epilepsy pathogenesis and screening antiepileptic drugs.
Drawings
Fig. 1 is a CRISPR/Cas9 knockout schematic.
FIG. 2 is a sequence position diagram of the target site on the genome of eef1b2 gene.
FIG. 3 is an electrophoresis detection diagram of 4 sgRNAs (M is a DNA Marker, and the numbers are 100bp, 200bp, 300bp, 400bp, 500bp, 700bp and 1000bp from bottom to top, and numbers 1, 2, 3 and 4 are sgRNA1, sgRNA2, sgRNA3 and sgRNA4 respectively).
FIG. 4 shows 4 sgRNA activity-verifying electropherograms (M is a DNA Marker, which is 100bp, 200bp, 300bp, 400bp, 500bp, 700bp, and 1000bp from bottom to top in sequence; Nos. 1, 2, and 3 are embryos after single-target injection of sgRNA1, Nos. 4, 5, and 6 are embryos after single-target injection of sgRNA2, Nos. 7, 8, and 9 are embryos after single-target injection of sgRNA3, Nos. 10, 11, and 12 are embryos after single-target injection of sgRNA4, and WT is a wild type).
FIG. 5 shows eef1b 2F 0 generation genotype identification electrophoretograms (M is DNA Marker, which is 100bp, 200bp, 300bp, 400bp, 500bp, 700bp, 1000bp from bottom to top in sequence; numbers 1-10 are F0 generation fish tail serial numbers, WT is wild type).
FIG. 6 shows eef1b 2F 1 generation genotype identification electrophoretograms (M is DNA Marker, which is 100bp, 200bp, 300bp, 400bp, 500bp, 700bp, 1000bp from bottom to top in sequence; numbers 1-15 are F1 generation fish tail serial numbers, WT is wild type).
FIG. 7 is a comparison of the sequencing peaks of the eef1b 2F 1 generation wild type and mutant.
Detailed Description
The present invention will be described in further detail with reference to the following examples and the accompanying drawings. The following examples are provided only for illustrating the present invention and are not intended to limit the scope of the present invention.
Example 1
1) Design CRISPONT gene knockout target site and detection primer
The genomic DNA sequence of The zebrafish eef1b2 Gene (Gene number: Gene ID:335370) was queried on The National Center for Biotechnology Information (NCBI), and The target site of The eef1b2 Gene was designed on The website The ZFIN (https:// ZFIN. org /) according to The CRISPR/Cas9 knock-out principle (FIG. 1). The selection of the target must follow this criterion: 5 '-GG- (N) 18-NGG-3'. The GG dinucleotide at the 5 'end is part of the T7 promoter, and the target site can be designed without limitation, but the NGG at the 3' end of the target site must be ensured. The target site must be selected within the domain of the gene to ensure that the insertion or deletion of the base of the target site can affect the entire domain of the eef1b2 gene to alter gene expression. The target site of the gene to be knocked out is located in the second exon of eef1b2 gene (FIG. 2), and the sequence of sg RNA is shown in Table 1.
Table 1sgRNA sequences
Primers were designed in Primer Premier 3.0 software (shown in table 2) from a genomic region of about 200bp upstream and downstream of the crispan target site of the eef1b2 gene.
TABLE 2 primer sequences
2) sgRNA synthesis and quality control
And (3) carrying out PCR experiment by using the designed primers to detect whether the designed sgRNA sequence is wrong. After confirming that the sgRNA was correct, the designed sgRNA was sent to a commercial company (south kyo jinsley biotechnology limited, hereinafter abbreviated as south kyo jinsley) for synthesis.
The four sgRNAs were centrifuged at 14000rpm for 10min to precipitate the RNA dry powder. Then, 15. mu.L of RNase-free double distilled water was added to dissolve the RNA dry powder. And performing quality detection on the four dissolved sgRNAs.
First, 1 μ L of sgRNA solution was taken and the concentration was measured on an ultraviolet spectrophotometer, and the concentration of each sgRNA and OD260/280 data were recorded. Secondly, 1 mu L of sgRNA solution is mixed with loading buffer for agarose gel electrophoresis, and whether the sgRNA is a single band is detected. Microinjection experiments can be performed if the sgRNA concentration is high (at least higher than 600 ng/. mu.l) and the electrophoretic band is a uniform band. The results are shown in fig. 3, which indicates that 4 sgRNA bands are single bands, contain no impurities, have high concentration, and can be used for microinjection experiments.
3) Activity validation of Single sgRNA
Before formal targeting, whether the designed sgRNA can be edited effectively needs to be tested. Thus, single sgRNA activity validation was performed. Cas9 protein (Nanjing Kisrei, Z03389-50) was complexed with 4 different sgRNAs as per the system in Table 3, giving a final concentration of Cas9 protein of 250 ng/. mu.l and a final concentration of sgRNAs of 100 ng/. mu.l. About 1nL of Cas9 protein and sgRNA cocktail was injected into fertilized eggs at one cell stage. The injected fertilized eggs were placed in E3 water and incubated at 28 ℃. Embryo phenotype is observed under a body type microscope, and the embryo which normally develops is screened for target site mutation analysis.
TABLE 3sgRNA and cas9 protein complexation System
4) Sanger sequencing to detect effectiveness of sgRNA
After microinjection is carried out on zebra fish embryos, partial normally developed early embryos are selected, whether the eef1b2 gene of the early embryos has mutation or not is detected, whether the selected target site has the effect or not is confirmed in advance, and whether microinjection operation is standard or not is determined.
a. Extraction of zebra fish genome
After 24 hours of fertilization (24hpf) of zebra fish embryos, wild type 1 tube (as a control) and injected experimental group embryos (3 tubes for each experimental group) are collected in 1.5mL Ep tubes (5 embryos per tube), and lysate is added to extract genomic DNA.
b. PCR amplification of target sequences
After extraction of genomic DNA, the PCR reaction system of Table 4 was used to amplify the DNA fragment of interest using the primer sequences of Table 2.
TABLE 4PCR reaction System
Shaking and mixing evenly, centrifuging, and carrying out amplification reaction on a PCR instrument. The reaction conditions are as follows: pre-denaturation at 95 ℃ for 5min, (denaturation at 95 ℃ for 30s, annealing at 56 ℃ for 30s, and elongation at 72 ℃ for 30s) for 35 cycles, and then at 72 ℃ for 8 min. After the reaction is finished, centrifuging the PCR product, taking 2 microliter of sample to sample on 1.3% agarose gel for electrophoresis, and detecting whether the size of the PCR product is correct or not.
c. And if the PCR product is correct, sending the PCR product to perform Sanger sequencing, wherein the result shows that the band is single as shown in FIG. 4, and the PCR product can be sent to a commercial company (biological engineering (Shanghai) corporation) to perform Sanger sequencing, the insertion or deletion information is preliminarily obtained from a sequencing peak diagram, the sgRNA knockout efficiency is obtained after comparison through a tide website, and formal injection is performed after the sgRNA is determined to be effective, wherein the result is shown in Table 5.
TABLE 5 Single sgRNA knockout efficiency
sgRNA1 | sgRNA2 | sgRNA3 | sgRNA4 | |
Knock out efficiency | 72% | 78% | 50% | 40% |
4) Microinjection of zebrafish embryos
Within 30min after fertilization, embryos were pipetted into a microinjection petri dish made of agarose.
Before microinjection, the Cas9 protein and 4 different sgrnas were mixed well to prepare a mixture, so that the final concentration of Cas9 protein was 250ng/μ l and the final concentration of each sgRNA was 100ng/μ l. About 1nL of Cas9 protein and sgRNA cocktail was injected into fertilized eggs at one cell stage. The injected fertilized eggs were placed in E3 water and incubated at 28 ℃. Embryo phenotype is observed under a body type microscope, and the embryo which normally develops is screened for target site mutation analysis.
Selecting 3 tubes of embryos (5 per tube) to detect the target knocking-out efficiency, wherein the detection steps are the same as the above steps, and culturing the rest embryos to two months old after the knocking-out is determined to be effective.
5) F0 generation mutant zebra fish screening
a. Extraction of zebra fish genome
After the embryo is cultured for two months, part of tail fin tissues of adult zebra fish are collected in a 1.5mL centrifuge tube, and lysate is added into an EP tube to extract genome DNA.
b. PCR amplification of target sequences
After extraction of genomic DNA, the PCR reaction system of Table 4 was used to amplify the DNA fragment of interest using the primer sequences of Table 2. The reaction conditions are as follows: pre-denaturation at 95 ℃ for 5min, (denaturation at 95 ℃ for 30s, annealing at 56 ℃ for 30s, and elongation at 72 ℃ for 30s) for 35 cycles, and then at 72 ℃ for 8 min. After the reaction is finished, centrifuging the PCR product, taking 2 microliter of sample to sample on 1.3% agarose gel for electrophoresis, and detecting whether the size of the PCR product is correct or not.
c. If the PCR product is correct, the PCR product is sent to perform Sanger sequencing, the experimental result is shown in FIG. 5, the result shows that the band is single, the PCR product can be sent to a commercial company (Biotechnology engineering (Shanghai) GmbH) to perform Sanger sequencing, the information of insertion or deletion is obtained from a sequencing peak diagram, and F0 zebra fish carrying the mutation is screened.
6) Generation F1 to obtain heritable zebrafish mutants
The zebra fish mutant F0 generation was confirmed by the previous series of screens, and then the F0 generation mutant was respectively crossed with wild zebra fish to obtain F1 generation embryos, which were cultured at 28 ℃ and the survival rate of F1 generation was observed at the early stage.
The zebrafish mutant was bred for up to 2-3 months for F1 generations if the presence of a mutation was detected from F1 generation embryos. And then, respectively shearing tails of each F1-generation adult zebra fish, and screening F1-generation mutants (the specific method is described in step 5), wherein the experimental result is shown in FIG. 6, and the result shows that the stripe is single and can be sent to a commercial company (biological engineering (Shanghai) GmbH) for Sanger sequencing. According to the analysis of the Sanger sequencing result of the screened F1 generation mutant, as shown in FIG. 7, according to the sequencing peak chart, the eef1b2 mutant inserts a 5bp fragment on the second exon and simultaneously deletes a 3bp fragment compared with the wild type sequence, thereby causing frame shift mutation. The red boxes indicate the sequence of sgRNA4, the blue square frame being the deleted 3 bp. Inserted 5bp fragment sequence: TTTGG, missing 3bp fragment sequence: and (4) CTT.
<110> Zhejiang Saishi Biotechnology Ltd
<120> eef1b2 gene knockout zebra fish epilepsy model and application thereof
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> eef1b2-sgRNA1 (Artificial sequence)
<400> 1
cctcaggtac gtaccctctc agg 23
<210> 2
<211> 23
<212> DNA
<213> eef1b2-sgRNA2 (Artificial sequence)
<400> 2
actgcaatat cagcctgaga ggg 23
<210> 3
<211> 23
<212> DNA
<213> eef1b2-sgRNA3 (Artificial sequence)
<400> 3
cactgcaata tcagcctgag agg 23
<210> 4
<211> 23
<212> DNA
<213> eef1b2-sgRNA4 (Artificial sequence)
<400> 4
gcagtgtttg atgctttgtc cgg 23
<210> 5
<211> 21
<212> DNA
<213> eef1b2-F (Artificial sequence)
<400> 5
accaacttta cctcaatgcc a 21
<210> 6
<211> 21
<212> DNA
<213> eef1b2-R (Artificial sequence)
<400> 6
ctggaaggct gaacacaaga g 21
<210> 7
<211> 5
<212> DNA
<213> 5bp insert (Artificial sequence)
<400> 7
<210> 8
<211> 3
<212> DNA
<213> 3bp deletion fragment (Artificial sequence)
<400> 8
Claims (4)
1. A zebra fish epilepsy model is characterized in that a zebra fish eef1b2 gene is knocked out by utilizing sgRNA combination, the sgRNA combination sequence is shown as SEQ ID No. 1-SEQ ID No.4, the zebra fish eef1b2 knocked-out gene is obtained by inserting a 5bp fragment into a second exon of a zebra fish eef1b2 gene and deleting a 3bp fragment, and the sequences of the zebra fish epilepsy model are shown as SEQ ID No.7 and SEQ ID No. 8.
2. An application of sgRNA combination in construction of a zebra fish epilepsy model is characterized in that the zebra fish epilepsy model is constructed by knocking out a zebra fish eef1b2 gene by the sgRNA combination, the sgRNA combination sequence is shown in SEQ ID No. 1-SEQ ID No.4, the zebra fish eef1b2 knocked-out gene is obtained by inserting a 5bp fragment into a second exon of a zebra fish eef1b2 gene and deleting a 3bp fragment, and the sequences are shown in SEQ ID No.7 and SEQ ID No. 8.
3. The use of the zebrafish epilepsy model of claim 1 for screening antiepileptic drugs.
4. A construction method of a zebra fish epilepsy model is characterized by comprising the following steps:
1) and sgRNA combination of the targeted CRISPONT gene and screening of detection primers: the sgRNA combined sequence is shown in SEQ ID NO.1 to SEQ ID NO.4, and the detection primer sequence is shown in SEQ ID NO.5 to SEQ ID NO. 6;
2) injecting a mixture of 4 sgrnas and Cas9 proteins into fertilized eggs of zebrafish;
3) f0 mutant zebra fish screening: screening out effective embryo, and culturing to adult fish to obtain F0 generation mutant zebra fish;
4) obtaining generations F1 of heritable zebrafish mutants: hybridizing F0 generation mutant zebra fish with wild zebra fish to obtain F1 generation embryos, screening the embryos with mutation, culturing to adult fish, screening to obtain F1 generation of heritable zebra fish mutant, compared with wild type, inserting 5bp fragment into the second exon of eef1b2 gene and deleting 3bp fragment, the sequence is shown as SEQ ID NO.7 and SEQ ID NO. 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111013471.2A CN113897360A (en) | 2021-08-31 | 2021-08-31 | Eef1b2 gene knockout zebra fish epilepsy model and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111013471.2A CN113897360A (en) | 2021-08-31 | 2021-08-31 | Eef1b2 gene knockout zebra fish epilepsy model and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113897360A true CN113897360A (en) | 2022-01-07 |
Family
ID=79188069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111013471.2A Pending CN113897360A (en) | 2021-08-31 | 2021-08-31 | Eef1b2 gene knockout zebra fish epilepsy model and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113897360A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111926017A (en) * | 2020-08-27 | 2020-11-13 | 南开大学 | Preparation and application of csf1ra gene-deleted zebra fish mutant |
-
2021
- 2021-08-31 CN CN202111013471.2A patent/CN113897360A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111926017A (en) * | 2020-08-27 | 2020-11-13 | 南开大学 | Preparation and application of csf1ra gene-deleted zebra fish mutant |
Non-Patent Citations (1)
Title |
---|
LISE LARCHER等: "New evidence that biallelic loss of function in EEF1B2 gene leads to intellectual disability", CLIN GENET, vol. 97, no. 4, XP071088620, DOI: 10.1111/cge.13688 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475300B (en) | Construction method and application of Ifit3-eKO1 gene knockout mouse animal model | |
CN105647969B (en) | Method for breeding zebra fish with stat1a gene deletion by gene knockout | |
CN115058424A (en) | Irf2bpl gene knockout zebra fish epilepsy model and construction method and application thereof | |
CN106282231B (en) | Construction method and application of mucopolysaccharide storage disease type II animal model | |
Dworkin et al. | Construction of a cloned library of expressed embryonic gene sequences from Xenopus laevis | |
CN111926017A (en) | Preparation and application of csf1ra gene-deleted zebra fish mutant | |
CN113817734A (en) | Hectd4 gene knockout zebra fish epilepsy model and construction method and application thereof | |
WO2022227692A1 (en) | Intermuscular bone-free crucian strain and cultivation method therefor | |
JP2022023037A (en) | Genome editing method | |
CN111154758A (en) | Method for knocking out zebra fish slc26a4 gene | |
CN110541002A (en) | method for constructing zebra fish asap1b gene knockout mutant by using CRISPR/Cas9 technology | |
CN110066805A (en) | The method of gene knockout breeding adgrf3b Gene Deletion zebra fish | |
CN113897361A (en) | Eef1b2 gene knockout zebra fish epilepsy model and construction method and application thereof | |
Nomura et al. | Microsatellite–centromere mapping in the Japanese eel (Anguilla japonica) by half-tetrad analysis using induced triploid families | |
CN114958857A (en) | Piggy gene knockout zebra fish neurodevelopment disorder model and construction method and application thereof | |
CN113957070A (en) | Chd2 gene knockout zebra fish epilepsy model and construction method and application thereof | |
CN113897399A (en) | Scn1lab gene knockout zebra fish epilepsy model and application thereof | |
CN113897362A (en) | Scn1lab gene knockout zebra fish epilepsy model and construction method and application thereof | |
CN114480497B (en) | Construction and application method of ep400 gene knockout zebra fish heart failure model | |
CN110894511A (en) | Method for breeding ppm1g gene mutant zebra fish by gene editing | |
CN113897360A (en) | Eef1b2 gene knockout zebra fish epilepsy model and application thereof | |
CN115261360A (en) | Method for constructing gata6 gene knockout zebra fish model | |
CN114774413A (en) | Construction method, detection method and application of zebra fish roe disorder model | |
CN115029352A (en) | Method for breeding adgrg1 gene-deleted zebra fish through gene knockout | |
CN110438159B (en) | Construction method of gene mutation mouse model for inducing myofibrillar myopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |